Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters (STREAM)

  • End date
    Aug 30, 2024
  • participants needed
  • sponsor
    Urotronic Inc.
Updated on 4 June 2022


Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 55 years of age.


Male subject diagnosed with a stricture in the anterior urethra that can be treated with the Optilume Urethral DCB. Thirty-Four (34) subjects will be enrolled at up to five (5) sites in the United States. Clinical follow-up will be conducted at 30 days, 3 months, 6 months, and 12 months post-treatment evaluating Lower Urinary Tract Symptoms (LUTS), sexual function, and voiding function. Semen quality parameters will be assessed at Baseline, 3 months, and 6 months post-treatment. Subjects with an abnormal semen quality result at 6 months will have an additional assessment at 12 months post-treatment and periodically thereafter until results return to normal.

Condition Urethral Stricture
Treatment Optilume Urethral DCB
Clinical Study IdentifierNCT05383274
SponsorUrotronic Inc.
Last Modified on4 June 2022


Yes No Not Sure

Inclusion Criteria

Male subjects between 22 and 55 years of age
Subject diagnosed with a stricture in the anterior urethra that is able to be treated with the Optilume Urethral DCB in accordance with the approved Instructions for Use
Subject is willing to provide written informed consent and comply with study required follow-up assessments
Subject able to provide viable semen samples and baseline semen quality characteristics are above reference values based on WHO criteria (average of 2 samples)
ejaculate volume ≥1.5mL
total sperm ≥39 million
sperm concentration ≥15 million/mL
total motility ≥40%
progressive motility ≥32%
morphology ≥4%

Exclusion Criteria

Subjects with a known hypersensitivity to paclitaxel or structurally related compounds
Subjects with a history of vasectomy or other condition that may inhibit semen/sperm production or ejaculatory function
Subjects currently taking 5-alpha reductase inhibitors, alpha-blockers, selective serotonin reuptake inhibitors, or hormone replacement therapy
Subject is unwilling to abstain or utilize a condom for 30 days after the procedure
Subject is unwilling to utilize highly effective contraception for 6 months after the procedure if partner is of childbearing potential
History of cancer in any body system that is not considered in complete remission
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note